Alexion Pharmaceuticals, Inc.
Treating muscle weakness with alkaline phosphatases
Last updated:
Abstract:
The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.
Status:
Grant
Type:
Utility
Filling date:
31 Mar 2017
Issue date:
30 Nov 2021